JPS55153715A - Prolonged granule of theophylline - Google Patents

Prolonged granule of theophylline

Info

Publication number
JPS55153715A
JPS55153715A JP6129479A JP6129479A JPS55153715A JP S55153715 A JPS55153715 A JP S55153715A JP 6129479 A JP6129479 A JP 6129479A JP 6129479 A JP6129479 A JP 6129479A JP S55153715 A JPS55153715 A JP S55153715A
Authority
JP
Japan
Prior art keywords
theophylline
prolonged
metal salt
granule
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP6129479A
Other languages
English (en)
Japanese (ja)
Other versions
JPS5753325B2 (enExample
Inventor
Keizaburo Ogawa
Tadashi Ukigaya
Satoru Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NIKKEN KAGAKU KK
Kowa Co Ltd
Original Assignee
NIKKEN KAGAKU KK
Nikken Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NIKKEN KAGAKU KK, Nikken Chemicals Co Ltd filed Critical NIKKEN KAGAKU KK
Priority to JP6129479A priority Critical patent/JPS55153715A/ja
Priority to US06/109,082 priority patent/US4261970A/en
Publication of JPS55153715A publication Critical patent/JPS55153715A/ja
Publication of JPS5753325B2 publication Critical patent/JPS5753325B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP6129479A 1979-05-18 1979-05-18 Prolonged granule of theophylline Granted JPS55153715A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP6129479A JPS55153715A (en) 1979-05-18 1979-05-18 Prolonged granule of theophylline
US06/109,082 US4261970A (en) 1979-05-18 1980-01-02 Theophylline sustained release granule

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6129479A JPS55153715A (en) 1979-05-18 1979-05-18 Prolonged granule of theophylline

Publications (2)

Publication Number Publication Date
JPS55153715A true JPS55153715A (en) 1980-11-29
JPS5753325B2 JPS5753325B2 (enExample) 1982-11-12

Family

ID=13167023

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6129479A Granted JPS55153715A (en) 1979-05-18 1979-05-18 Prolonged granule of theophylline

Country Status (2)

Country Link
US (1) US4261970A (enExample)
JP (1) JPS55153715A (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4465660A (en) * 1981-04-01 1984-08-14 Mead Johnson & Company Sustained release tablet containing at least 95 percent theophylline
US4547358A (en) * 1980-05-06 1985-10-15 Mead Johnson & Company Sustained release tablet containing at least 95 percent theophylline
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
US4708874A (en) * 1985-03-13 1987-11-24 Rijksuniversiteit Groningen Devices for the controlled release of active substances, as well as process for the preparation thereof

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056122B2 (ja) * 1980-05-21 1985-12-09 塩野義製薬株式会社 徐放性製剤
SE8103843L (sv) * 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
FR2535202B1 (fr) * 1982-11-03 1985-08-09 Fabre Sa Pierre Comprimes de theophylline a liberation controlee et leur procede de fabrication
DE3435325A1 (de) * 1983-04-09 1986-04-17 Nikken Chemicals Co., Ltd., Tokio/Tokyo Langzeitwirkende theophyllin-tablette und verfahren zu deren herstellung
FR2570603B1 (fr) * 1983-04-09 1987-07-17 Nikken Chemicals Co Ltd Pastille pharmaceutique de theophylline a liberation prolongee et son procede de preparation
ZA836031B (en) * 1983-08-16 1985-02-27 Verex Lab Constant release rate solid dosage theophylline formulation
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
JPS62103012A (ja) * 1985-10-23 1987-05-13 Eisai Co Ltd 多重顆粒
US4837032A (en) * 1986-02-04 1989-06-06 Farval Ag Theophylline sustained release tablet
IL78017A (en) * 1986-03-03 1989-06-30 Yissum Res Dev Co Sustained release tablets of theophylline
JP2643222B2 (ja) * 1988-02-03 1997-08-20 エーザイ株式会社 多重層顆粒
US4925675A (en) * 1988-08-19 1990-05-15 Himedics, Inc. Erythromycin microencapsulated granules
US4925674A (en) * 1988-08-25 1990-05-15 Himedics, Inc. Amoxicillin microencapsulated granules
US4966770A (en) * 1989-07-26 1990-10-30 Himedics, Inc. Prednisone microencapsulated granules
DE3929864A1 (de) * 1989-09-08 1991-03-14 Nordmark Arzneimittel Gmbh Verfahren zur herstellung von theophyllin-pellets
US5162110A (en) * 1990-12-19 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding theophylline to ion exchange resins
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6080428A (en) * 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
GB0227948D0 (en) * 2002-11-29 2003-01-08 Cipla Ltd Pharmaceutical combinations comprising b-2 adrenoreceptor agonists and xanthines
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US7538652B2 (en) * 2006-08-29 2009-05-26 International Business Machines Corporation Electrical component tuned by conductive layer deletion
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2928769A (en) * 1957-07-22 1960-03-15 Strong Cobb And Company Inc Production of controlled release medicaments
US3079303A (en) * 1958-12-11 1963-02-26 Smith Kline French Lab Basic tablet granulation and process of using same
US3062720A (en) * 1959-05-20 1962-11-06 Philips Roxane Sustained release pharmaceutical tablet
NL264748A (enExample) * 1960-05-17
US3102845A (en) * 1960-11-18 1963-09-03 Mcneilab Inc Pharmaceutical tablet
US3133863A (en) * 1961-03-10 1964-05-19 Strong Cobb Arner Inc Sustained release therapeutic tablet compositions comprising organic solvent-gelled gums
US3136695A (en) * 1961-03-10 1964-06-09 Strong Cobb Arner Inc Anhydrous thixotropic gel sustained release therapeutic compositions and method of preparation
US3115441A (en) * 1962-06-06 1963-12-24 Victor M Hermelin Timed release pharmaceutical preparations and method of making the same
US3148124A (en) * 1962-06-12 1964-09-08 William E Gaunt Method of preparing sustained release pharmaceutical tablets
US3629393A (en) * 1969-09-11 1971-12-21 Nikken Chemicals Co Ltd Release-sustaining-tablet
US3773920A (en) * 1971-07-14 1973-11-20 Nikken Chemicals Co Ltd Sustained release medicinal composition

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547358A (en) * 1980-05-06 1985-10-15 Mead Johnson & Company Sustained release tablet containing at least 95 percent theophylline
US4465660A (en) * 1981-04-01 1984-08-14 Mead Johnson & Company Sustained release tablet containing at least 95 percent theophylline
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
US4708874A (en) * 1985-03-13 1987-11-24 Rijksuniversiteit Groningen Devices for the controlled release of active substances, as well as process for the preparation thereof

Also Published As

Publication number Publication date
JPS5753325B2 (enExample) 1982-11-12
US4261970A (en) 1981-04-14

Similar Documents

Publication Publication Date Title
DK553283D0 (da) Laegemiddeladsorbatsammensaetning indeholdende magnesiumtrisilicat
JPS53113008A (en) Constant rate releasing preparation
HUT75230A (en) Novel pharmaceutical composition for the preparation of a stable powder containing an active principle comprising an association of acetylsalicylic acid and metoclopramide
JPS5350316A (en) Drug composition for oral administration
JPS56138111A (en) Suppository containing unsaturated fatty acid or salt thereof
EP0310126A3 (en) Derivatives of pyrocatechol-carboxylic acid, their preparation and use as active ingredients in medicines
JPS57140723A (en) Preventing composition for hyperlipemia due to neutral fat
JPS5661311A (en) Thial amide or prolonged pharmaceutical preparation comprising its salt
JPS5545601A (en) Long-acting cephalexin and its preparation
JPS56138110A (en) Suppository containing citric acid or salt thereof
JPS5470428A (en) Carcinostatic agent
ATE322896T1 (de) Verbesserte pharmazeutische zusammensetzung mit einem ppar-alpha-mittel und verfahren zu ihrer herstellung
JPS5329916A (en) Ready absorption oryzanol preparation
JPS5686114A (en) Pharmaceutical composition for suppository
Hattab Absorption of fluoride following inhalation and ingestion of alginate impression materials
JPS5742623A (en) Antialcoholic adipohepatic agent
JPS57144214A (en) Pharmaceutical preparation for rectum medication
Nottage et al. Effect of lithium on voluntary alcohol consumption by low and high preference mouse strains
JPS5640607A (en) Drug composition
JPS6413026A (en) Antiviral agent
JPS5572108A (en) Preparation for transcutaneous administration, composed mainly of nitroglycerine
JPS57158719A (en) Rectal administration pharmaceutical
JPS643123A (en) Remedy for skin inflammation
JPS57146711A (en) Material for administering pharmaceutically active substance
JPS5634624A (en) Central nervous system depressant